Colinz Laboratories Limited disclosed its unaudited financial results for the quarter and half year ended September 30, 2026, following a board meeting held on October 29, 2026. The meeting commenced at 3:30 PM and concluded at 5:30 PM.

Financial Performance (Quarter Ended September 30, 2026)

  • Revenue from operations: Rs 155.00 lakh
  • Other income: Rs 13.91 lakh
  • Total income: Rs 168.91 lakh
  • Total expenses: Rs 150.26 lakh
  • Profit before tax: Rs 18.65 lakh
  • Tax expense: Rs 6.00 lakh (current tax)
  • Net profit: Rs 12.65 lakh
  • Other comprehensive income: Rs 0.14 lakh (change in fair value of equity investments)
  • Total comprehensive income: Rs 12.79 lakh
  • Basic and diluted EPS: Rs 0.50

Financial Performance (Half Year Ended September 30, 2026)

  • Revenue from operations: Rs 279.09 lakh
  • Other income: Rs 26.08 lakh
  • Total income: Rs 305.17 lakh
  • Total expenses: Rs 272.73 lakh
  • Profit before exceptional items: Rs 32.44 lakh
  • Exceptional items: Rs 276.33 lakh (profit on sale of fixed assets, net)
  • Profit before tax: Rs 308.77 lakh
  • Tax expense: Rs 56.00 lakh (current tax)
  • Net profit: Rs 252.77 lakh
  • Other comprehensive income: Rs 13.80 lakh
  • Total comprehensive income: Rs 266.57 lakh
  • Basic and diluted EPS: Rs 10.03

Comparative Financials

Quarterly Comparison (Q2 FY27 vs Q1 FY27):

  • Revenue increased from Rs 124.09 lakh to Rs 155.00 lakh
  • Net profit decreased from Rs 240.12 lakh to Rs 12.65 lakh
  • EPS decreased from Rs 9.53 to Rs 0.50

Year-over-Year Half Yearly Comparison (H1 FY27 vs H1 FY26):

  • Revenue decreased from Rs 295.41 lakh to Rs 279.09 lakh
  • Net profit increased significantly from Rs 25.97 lakh to Rs 252.77 lakh
  • EPS increased from Rs 1.03 to Rs 10.03

Balance Sheet Highlights (as of September 30, 2026)

  • Total assets: Rs 1,473.64 lakh
  • Non-current assets: Rs 171.35 lakh (including property, plant & equipment: Rs 42.61 lakh, investments: Rs 126.40 lakh)
  • Current assets: Rs 1,302.29 lakh (including inventories: Rs 82.99 lakh, trade receivables: Rs 90.92 lakh, cash & cash equivalents: Rs 41.95 lakh, other bank balances: Rs 1,085.30 lakh)
  • Total equity: Rs 1,270.88 lakh
  • Current liabilities: Rs 183.50 lakh

Cash Flow Statement (Half Year Ended September 30, 2026)

  • Net cash used in operating activities: Rs (131.81) lakh
  • Net cash from investing activities: Rs 383.28 lakh (primarily from investments in shares & securities: Rs 382.34 lakh)
  • Net cash from financing activities: Rs 22.87 lakh
  • Net increase in cash and cash equivalents: Rs 274.34 lakh
  • Ending cash balance: Rs 1,127.25 lakh

Regulatory Compliance and Additional Information

  • The financial results were prepared in accordance with Ind AS 34 and SEBI Circular CIR/CF/FAC/62/2016 dated July 5, 2016
  • Statutory auditors Vora & Associates issued a limited review report dated October 29, 2026, with no material misstatements identified
  • The company is primarily engaged in manufacturing pharmaceutical formulations with no other reportable segments
  • Previous period figures have been regrouped/rearranged/reclassified where necessary
  • Deferred tax provision will be accounted for at year-end
  • Results are available on BSE website (www.bseindia.com) and company website (www.findoc-cll.in)